BRD2 and neoplasm: Together, these strategies enhance the precision of BET targeting; yet a recent multi-tumor analysis demonstrated that adaptive BRD2 overexpression can sustain transcriptional programs and drive resistance, emphasizing the need to integrate combination or sequential therapies into future treatment approaches (39).